Article

2015: The Year in Multiple Sclerosis News

Author(s):

Davy James, Managing Editor

Most read multiple sclerosis articles from the past year.

[<a href="//storify.com/pharmacytimes/2015-the-year-in-multiple-sclerosis-news" target="_blank">View the story "2015: The Year in Multiple Sclerosis News" on Storify</a>]

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Caregiver holding elderly man's hand -- Image credit: Chinnapong | stock.adobe.com
Health care worker looking at MRI scans of dementia -- Image credit: Atthapon | stock.adobe.com
Related Content
Hidradenitis Suppurative, FDA, Dermatology, Bimzelx | Image Credit: © Gorodenkoff | stock.adobe.com
Published: November 20th 2024 | Updated: November 20th 2024

FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa

Ashley Gallagher, Associate Editor
Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development
August 23rd 2024

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Ashley Gallagher, Associate Editor
FDA Approval, Neurology, AADC Deficiency | Image Credit: Aquir | stock.adobe.com
Published: November 14th 2024 | Updated: November 14th 2024

FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency

Ashley Gallagher, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
Biosimilar, Ocrelizumab, Multiple Sclerosis | Image Credit: ralwel - stock.adobe.com
November 12th 2024

Proposed Biosimilar to Ocrelizumab Shows Comparability With Reference Product

Ashley Gallagher, Associate Editor
Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate